莱斯康制药 LXRX 深 沪
等待开盘 11-06 09:30:00 美东时间
1.58
+0.100
+6.76%
华盛通- 最 高1.6399
- 今 开1.57
- 成交量 307.26万股
- 最 低 1.51
- 昨 收 1.48
- 总市值 7.03亿
- 52周最高 2.68
- 市盈率 静 --
- 换手率 0.69%
- 52周最低 1.10
- 委 比 -41.68%
- 总股本 4.45亿
- 历史最高 19.62
- 量 比 2.17
- 振 幅 8.78%
- 历史最低 0.2836
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexicon Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
Lexicon Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
今天 00:15
Lexicon Pharmaceuticals Q3 EPS $(0.03) Beats $(0.06) Estimate, Sales $11.250M Beat $4.142M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $11.250 mill...
11-05 20:50
莱斯康制药收涨1.41%，成交额289.16万美元
11月3日，莱斯康制药（LXRX）收涨1.41%，报1.44美元，成交额289.16万美元，市值6.41亿美元。 行情数据 • 开盘价：1.44美元 • 最高价...
11-03 06:57
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced it will release its third quarter 2026 financial results on November 5, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to discuss the results and provide a business update. Participants can access the webcast via the Events page on the Company’s website at https://investors.lexpharma.com/. Those wishing to ask questions can reg...
10-29 12:30
莱斯康制药收跌4.7%，成交额378.95万美元
10月24日，莱斯康制药（LXRX）收跌4.7%，报1.42美元，成交额378.95万美元，市值6.32亿美元。 行情数据 • 开盘价：1.5美元 • 最高价...
10-24 06:01
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Mineralys Therapeutics appoints Kristine Peterson and Lonnel Coats to its Board of Directors, adding extensive commercial and product launch experience ahead of the December 22 PDUFA target date for lorundrostat, a treatment for uncontrolled or resistant hypertension. Both executives bring deep expertise in launching and commercializing therapies, particularly in cardiovascular and metabolic disease. Peterson, with over three decades in biopharma...
10-19 20:05
莱斯康制药收跌7.88%，成交额313.21万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:59
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consul...
10-06 15:51
美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.
09-28 18:39
